At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 14 enrolled
Drug / intervention
Cosopt (combination eyedrop of dorzolamide and timolol)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Effect of Myocilin Genetic Variants on Intraocular Pressure and Blood Pressure Variation in Sitting and Supine Positions.
In Brief
A Phase 4 clinical trial evaluating Cosopt (combination eyedrop of dorzolamide and timolol) for Glaucoma. Completed, enrolled 14 participants across 1 site.
Detailed Summary
The purpose of this study is to determine if one of the genes that can cause glaucoma, called myocilin, are associated with larger eye pressure and blood pressure changes in sitting and lying down positions without glaucoma drug treatment and with glaucoma drug treatment with a combination medication called Cosopt® (Merck \& Co., Inc.).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGlaucoma
CountriesUnited States
CollaboratorsMerck Sharp & Dohme LLC
Timeline
Phase 4CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedMay 2009
Enrollment StartAug 2009
Primary CompletionJul 2012
TodayJul 2026
First PostedMay 21, 2009
Enrollment StartAug 4, 2009
Primary CompletionJul 18, 2012
TodayJul 2, 2026
Enrollment to primary: 3.0 yearsPosted 17.1 years ago
Interventions
Cosopt (combination eyedrop of dorzolamide and timolol)drug
One drop in each eye every twelve hours for six weeks